These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Updates in Drug Treatment of Severe Hypertriglyceridemia. Gouni-Berthold I; Schwarz J; Berthold HK Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858 [TBL] [Abstract][Full Text] [Related]
64. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection. Pandey P; Zhao C; Liu B Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321 [TBL] [Abstract][Full Text] [Related]
65. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Berman AN; Blankstein R Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838 [TBL] [Abstract][Full Text] [Related]
66. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727 [TBL] [Abstract][Full Text] [Related]
67. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550 [TBL] [Abstract][Full Text] [Related]
68. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]
69. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
70. Hypobetalipoproteinemia and abetalipoproteinemia. Welty FK Curr Opin Lipidol; 2014 Jun; 25(3):161-8. PubMed ID: 24751931 [TBL] [Abstract][Full Text] [Related]
71. Gene Silencing of Angiopoietin-like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line. Rossi I; Marodin G; Lupo MG; Adorni MP; Papotti B; Dall'Acqua S; Ferri N Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612519 [TBL] [Abstract][Full Text] [Related]
73. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Spagnuolo CM; Hegele RA Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828 [TBL] [Abstract][Full Text] [Related]
74. Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. Wong ND; Rosenblit PD; Greenfield RS Cardiovasc Diagn Ther; 2017 Apr; 7(Suppl 1):S11-S20. PubMed ID: 28529918 [TBL] [Abstract][Full Text] [Related]
76. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Gaudet D; Karwatowska-Prokopczuk E; Baum SJ; Hurh E; Kingsbury J; Bartlett VJ; Figueroa AL; Piscitelli P; Singleton W; Witztum JL; Geary RS; Tsimikas S; O'Dea LSL; Eur Heart J; 2020 Oct; 41(40):3936-3945. PubMed ID: 32860031 [TBL] [Abstract][Full Text] [Related]
77. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
78. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Brandts J; Ray KK Nat Rev Cardiol; 2023 Sep; 20(9):600-616. PubMed ID: 37055535 [TBL] [Abstract][Full Text] [Related]
79. ANGPTL3 as therapeutic target. Kersten S Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310 [TBL] [Abstract][Full Text] [Related]